1. Children Exposed or Unexposed to Human Immunodeficiency Virus: Weight, Height, and Body Mass Index During the First 5 Years of Life—A Danish Nationwide Cohort. (4th July 2019) Authors: Moseholm, Ellen; Helleberg, Marie; Sandholdt, Håkon; Katzenstein, Terese L; Storgaard, Merete; Pedersen, Gitte; Johansen, Isik S; Weis, Nina Journal: Clinical infectious diseases Issue: Volume 70:Number 10(2020) Page Start: 2168 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Issue 6 (30th July 2014) Authors: Hézode, Christophe; Hirschfield, Gideon M; Ghesquiere, Wayne; Sievert, William; Rodriguez-Torres, Maribel; Shafran, Stephen D; Thuluvath, Paul J; Tatum, Harvey A; Waked, Imam; Esmat, Gamal; Lawitz, Eric J; Rustgi, Vinod K; Pol, Stanislas; Weis, Nina; Pockros, Paul J; Bourlière, Marc; Serfaty, Law... Journal: Gut Issue: Volume 64:Issue 6(2015) Page Start: 948 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Direct acting antiviral treatment of chronic hepatitis C in Denmark: factors associated with and barriers to treatment initiation. (3rd July 2018) Authors: Sølund, Christina; Hallager, Sofie; Pedersen, Martin S.; Fahnøe, Ulrik; Ernst, Anja; Krarup, Henrik B.; Røge, Birgit T.; Christensen, Peer B.; Laursen, Alex L.; Gerstoft, Jan; Bélard, Erika; Madsen, Lone G.; Schønning, Kristian; Pedersen, Anders G.; Bukh, Jens; Weis, Nina Journal: Scandinavian journal of gastroenterology Issue: Volume 53:Number 7(2018) Page Start: 849 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting. (24th November 2021) Authors: Mollerup, Annette; Henriksen, Marius; Larsen, Sofus Christian; Bennetzen, Anita Selmer; Simonsen, Mette Kildevæld; Kofod, Linette Marie; Knudsen, Jenny Dahl; Nielsen, Xiaohui Chen; Weis, Nina; Heitmann, Berit Lilienthal Journal: BMJ Issue: Volume 375(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Issue 9973 (21st March 2015) Authors: Sulkowski, Mark; Hezode, Christophe; Gerstoft, Jan; Vierling, John M; Mallolas, Josep; Pol, Stanislas; Kugelmas, Marcelo; Murillo, Abel; Weis, Nina; Nahass, Ronald; Shibolet, Oren; Serfaty, Lawrence; Bourliere, Marc; DeJesus, Edwin; Zuckerman, Eli; Dutko, Frank; Shaughnessy, Melissa; Hwang, Peggy... Journal: Lancet Issue: Volume 385:Issue 9973(2015) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants. Issue 3 (5th June 2019) Authors: Jensen, Sanne Brun; Fahnøe, Ulrik; Pham, Long V.; Serre, Stéphanie Brigitte Nelly; Tang, Qi; Ghanem, Lubna; Pedersen, Martin Schou; Ramirez, Santseharay; Humes, Daryl; Pihl, Anne Finne; Filskov, Jonathan; Sølund, Christina Søhoel; Dietz, Julia; Fourati, Slim; Pawlotsky, Jean‐Michel; Sarrazin, Chr... Journal: Hepatology Issue: Volume 70:Issue 3(2019) Page Start: 771 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (May 2022) Authors: Blach, Sarah; Terrault, Norah A; Tacke, Frank; Gamkrelidze, Ivane; Craxi, Antonio; Tanaka, Junko; Waked, Imam; Dore, Gregory J; Abbas, Zaigham; Abdallah, Ayat R; Abdulla, Maheeba; Aghemo, Alessio; Aho, Inka; Akarca, Ulus S; Alalwan, Abduljaleel M; Alanko Blomé, Marianne; Al-Busafi, Said A; Aleman... Journal: Lancet gastroenterology and hepatology Issue: Volume 7:Number 5(2022) Page Start: 396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome. Issue 2 (25th November 2020) Authors: Fahnøe, Ulrik; Pedersen, Martin S.; Sølund, Christina; Ernst, Anja; Krarup, Henrik B.; Røge, Birgit T.; Christensen, Peer B.; Laursen, Alex L.; Gerstoft, Jan; Thielsen, Peter; Madsen, Lone G.; Pedersen, Anders G.; Schønning, Kristian; Weis, Nina; Bukh, Jens Journal: Journal of viral hepatitis Issue: Volume 28:Issue 2(2021) Page Start: 302 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗